Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg partner site, Heidelberg, Germany; German Center for Lung Research (DZL), Heidelberg partner site, Heidelberg, Germany.
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Lung Research (DZL), Heidelberg partner site, Heidelberg, Germany.
Cell. 2021 Feb 4;184(3):571-573. doi: 10.1016/j.cell.2021.01.008. Epub 2021 Jan 27.
The advent of immune checkpoint blockers for cancer therapy has spawned great interest in identifying molecular features reflecting the complexity of tumor immunity, which can subsequently be leveraged as predictive biomarkers. In a thorough big-data approach analyzing the largest series of homogenized molecular and clinical datasets, Litchfield et al. identified a set of genomic biomarkers that identifies immunotherapy responders across cancer types.
免疫检查点抑制剂在癌症治疗中的应用引发了人们极大的兴趣，促使人们去寻找反映肿瘤免疫复杂性的分子特征，这些特征随后可作为预测生物标志物加以利用。在一项对最大系列均质化分子和临床数据集进行全面大数据分析的研究中，Litchfield 等人确定了一组基因组生物标志物，可用于鉴定跨癌症类型的免疫治疗应答者。
